Company Overview
| Stock Name | Clover Bio-B |
|---|---|
| Stock Code | 02197 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家處於臨床試驗階段的全球性生物技術公司,致力於為傳染性疾病以及癌症及自身免疫性疾病開發新型疫苗及生物治療候選產品。 |
| Listing Date | 2021-11-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市中國(四川)自由貿易試驗區成都高新區天府大道北段1480號高新孵化園1號樓B5-19 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.cloverbiopharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 13.38 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 6,690 |
| Par Value | To be extracted |
| Offer Period | 2021-10-25 to 2021-10-28 |
| Global Offering Shares | 150,000,000 shares |
| HK Public Offer Shares (Initial) | 15,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 30,000lots (Pool A15,000lots,Pool B15,000lots) |
| International Placing Shares (Initial) | 135,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,158,114,723 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 53.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,007,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 6,690 |
| 2 lots | 1,000 | HK$ 13,380 |
| 3 lots | 1,500 | HK$ 20,070 |
| 4 lots | 2,000 | HK$ 26,760 |
| 5 lots | 2,500 | HK$ 33,450 |
| 6 lots | 3,000 | HK$ 40,140 |
| 7 lots | 3,500 | HK$ 46,830 |
| 8 lots | 4,000 | HK$ 53,520 |
| 9 lots | 4,500 | HK$ 60,210 |
| 10 lots | 5,000 | HK$ 66,900 |
| 12 lots | 6,000 | HK$ 80,280 |
| 14 lots | 7,000 | HK$ 93,660 |
| 16 lots | 8,000 | HK$ 107,040 |
| 18 lots | 9,000 | HK$ 120,420 |
| 20 lots | 10,000 | HK$ 133,800 |
| 30 lots | 15,000 | HK$ 200,700 |
| 40 lots | 20,000 | HK$ 267,600 |
| 50 lots | 25,000 | HK$ 334,500 |
| 60 lots | 30,000 | HK$ 401,400 |
| 70 lots | 35,000 | HK$ 468,300 |
| 80 lots | 40,000 | HK$ 535,200 |
| 90 lots | 45,000 | HK$ 602,100 |
| 100 lots | 50,000 | HK$ 669,000 |
| 120 lots | 60,000 | HK$ 802,800 |
| 140 lots | 70,000 | HK$ 936,600 |
| 160 lots | 80,000 | HK$ 1,070,400 |
| 180 lots | 90,000 | HK$ 1,204,200 |
| 200 lots | 100,000 | HK$ 1,338,000 |
| 300 lots | 150,000 | HK$ 2,007,000 |
| 400 lots | 200,000 | HK$ 2,676,000 |
| 500 lots | 250,000 | HK$ 3,345,000 |
| 600 lots | 300,000 | HK$ 4,014,000 |
| 700 lots | 350,000 | HK$ 4,683,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 800 lots | 400,000 | HK$ 5,352,000 |
| 900 lots | 450,000 | HK$ 6,021,000 |
| 1,000 lots | 500,000 | HK$ 6,690,000 |
| 1,200 lots | 600,000 | HK$ 8,028,000 |
| 1,400 lots | 700,000 | HK$ 9,366,000 |
| 2,000 lots | 1,000,000 | HK$ 13,380,000 |
| 4,000 lots | 2,000,000 | HK$ 26,760,000 |
| 15,000 lots | 7,500,000 | HK$ 100,350,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.67B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +263% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 15,229,208,607 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损约人民币912.9百万元 |
| Period-End Cash Balance | 人民币516.2百万元 |
| Listing Expenses | ~HK$ 135,300,000 |
| Listing Expenses / Funds Raised | ~6.74% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Other income and gains, net | 16,908 | 24,341 |
| Administrative expenses | -45,979 | |
| Profit before tax | -48,469 | |
| Profit for the year | -48,309 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 12.98 |
|---|---|
| First Day Open | HK$ 13.38 |
| First Day Change | -2.99% |
| First Day Volume | 33982000.0 |
| First Day Turnover | 448171000.0 |
| Use of Proceeds | 約65%,或1,215.6百萬港元將用于我們核心產品及相關產品的研發、生產及商業化;
約22.5%,或420.8百萬港元將用于我們管線中其他產品的研發、生產及商業化;
約12.5%,或233.8百萬港元將用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Aranda Investments Pte. Ltd. | 155,589,330 HKD | — | 7.80% | — | 6 months | 2022-05-05 |
| 2 | Athos Asia Event Driven Master Fund | 116,686,980 HKD | — | 5.80% | — | 6 months | 2022-05-05 |
| 3 | Hillhouse Funds | 171,143,580 HKD | — | 8.50% | — | 6 months | 2022-05-05 |
| 4 | Oceanpine Capital Management Limited | 116,686,980 HKD | — | 5.80% | — | 6 months | 2022-05-05 |
| 5 | OrbiMed Funds | 194,484,990 HKD | — | 9.70% | — | 6 months | 2022-05-05 |
| 6 | Rock Springs Capital Master Fund LP | 147,808,860 HKD | — | 7.40% | — | 6 months | 2022-05-05 |
| 7 | Springhill Master Fund Limited | 77,791,320 HKD | — | 3.90% | — | 6 months | 2022-05-05 |
| 8 | Superstring Capital Master Fund LP | 58,343,490 HKD | — | 2.90% | — | 6 months | 2022-05-05 |
| 9 | Toroa Master Fund | 38,895,660 HKD | — | 1.90% | — | 6 months | 2022-05-05 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 梁朋 | — |
| Company Secretary | Brian KREX、馮寶婷 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 梁博士持股約17.83%、梁果先生持股約1.51%、JNRY約8.53%、AUT-XXI約6.29%、Aranda約8.53%、上海天合約6.04%、汪世碧女士約8.69%、Elasa約6.31%。 |
|---|




